Overview of the drug development pipeline for dry age-related macular degeneration
It has been observed that dry age-related macular degeneration (AMD) initially develops in one eye, and afterward, it develops in both the eyes. Symptoms of dry macular degeneration include blurred vision and reduction in central vision due to thinning of the macula. Dry AMD, if not treated, may cause further deterioration of vision as it affects the ability to read, drive, and to recognize faces. The major factors that can increase the risk of getting dry AMD include, age over 65, family history, smoking, obesity, and persons affected by cardiovascular disease. Complications due to dry AMD can progress it to a more advanced stage of AMD, i.e. wet AMD, which can result in rapid loss of vision if left untreated. The most efficient approach for the treatment of dry macular degeneration is monotherapy.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for the treatment of dry macular degeneration. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Pipeline analysis report on drug development for dry age-related macular degeneration: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of dry age-related macular degeneration. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- Alkeus Pharmaceuticals
- Allergan
- Apellis Pharmaceuticals
- Astellas Pharma
- Cell Cure Neurosciences
Therapeutic assessment of the drug development pipeline for dry age-related macular degeneration by route of administration
- Intravitreal
- Oral
- Subretinal
- Topical
- Subcutaneous
- Unknown
The intravitreal route of administration (ROA) involves the administration of the drug into the vitreous, which is near the retina at the back of the eye as it will have a more direct effect on the target cells. In the oral technique, the drug molecules are directly delivered into the mouth cavity.
Therapeutic assessment of the drug development pipeline for dry age-related macular degeneration by therapy
- Monotherapy
- Combination Therapy
- Monotherapy/ Combination Therapy
- Unknown
According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for treatment of dry macular degeneration are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug molecules in the various development stages for dry age-related macular degeneration?
- What are the companies that are currently involved in the development of drug molecules for dry age-related macular degeneration?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.